efficacy and safety study of ryanodex as adjuvant treatment in subjects with psychostimulant drug-induced toxicity (pdit)

Conditions: Drug Toxicity Psychotropic Agents Psychostimulants

Summary: ryanodex is being investigated as a potential adjuvant treatment for people suffering from psychostimulant drug-induced toxicity (pdit), a life-threatening medical condition that results mainly from the abuse of certain illicit drugs, most notably methamphetamine, and related forms (mdmc or "molly"; mdma or "ecstasy"). ryanodex is approved for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for prevention of malignant hyperthermia in patients at high risk and in this study, will be investigated for the treatment of pdit. the hypothesis of this study is that administration of ryanodex as adjuvant treatment to standard of care (soc) will improve the clinical outcome compared with soc alone, in subjects with psychostimulant drug induced toxicity. current soc is defined as body cooling and supportive measures.

this study will be conducted at pre-hospital emergency care (phec) facilities. the phecs are medical units that are fully equipped and staffed to provide adequate emergency medical care to patients with pdit. the study is designed to evaluate the safety and efficacy of ryanodex in an on0site pre-hospital emergency setting where subjects are anticipated to be treated over a short period of time and then transferred to another medical facility or released. after screening and diagnosis of pdit, soc treatment will be initiated. subjects eligible for the study will be randomized to either receive soc + ryanodex or to receive soc only. study subjects are expected to remain at the study site for a maximum of 6 hours post-baseline.

Eligibility criteria:
inclusion criteria: male and non-pregnant subjects diagnosed with psychostimulant drug induced toxicity as evidenced by all of the following: core body temperature of greater than or equal to 39.5 degrees c; organ dysfunction, as evidenced by a logistic organ dysfunction system score of greater than or equal to 6 (in the event of any delay in obtaining the results for baseline lods score determination, subject may be enrolled. after enrollment, if the pending baseline lods score turns out to be less than 6, the subject will be withdrawn from the study and replaced); known or suspected us of a psychostimulant drug in the judgment of the investigator; negative blood pregnancy test for females (in the event of any delay in obtaining pregnancy test result, subject may be enrolled and randomized if all of the other eligibility criteria are met). exclusion criteria: diagnosed with or is suspected to have an acute, clinically severe infection, which may, in the opinion of the investigator, may increase the subject's risk for participating in the study an/or may impair the ability of performing and/or interpreting study assessments; severe hyperthermia secondary to a condition other than a psychostimulant drug-induced toxicity; likelihood of head trauma in the past 3 months, or other systemic disease that might increase the subject's risk for participating in the study and/or may impair the ability of performing and/or interpreting study assessments; positive pregnancy test or evidence of active lactation; known history of allergy or hypersensitivity to dantrolene; known history of seizure disorders or epilepsy; current or prior use (within the past 2 weeks) of calcium channel blockers. -